<DOC>
	<DOC>NCT01902628</DOC>
	<brief_summary>This prospective observational study will evaluate the efficacy and safety of Mircera (methoxy polyethylene glycol-epoetin beta) in chronic kidney disease patients not on dialysis with renal anemia. Patients initiated on treatment with Mircera according to the Summary of Product Characteristics and standard clinical practice will be followed for 10 months.</brief_summary>
	<brief_title>OPTIMA: An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Patients With Chronic Kidney Disease Stages 3 &amp; 4 Not on Dialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Adult patients, &gt;/= 18 years of age Patients with chronic kidney disease (CKD) not on dialysis with renal anemia (CKD Stages 3 &amp; 4) Initiated on Mircera treatment (patients may have received Mircera treatment for up to 3 months before study enrollment) Life expectancy &gt; 10 months Malignant disease Significant or acute bleeding Poorly controlled hypertension Blood transfusion during the previous 2 months Hypersensitivity to Mircera or any of its excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>